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Background. Nonselective β-blockers (NSBB) have been associated with increased incidence of paracentesis-induced circulatory
dysfunction (PICD) and reduced survival in patients with cirrhosis and refractory ascites. Aim. To prospectively evaluate a
hemodynamic response to NSBB in cirrhotics listed for liver transplantation with refractory ascites undergoing large volume
paracentesis (LVP). Methods. Patients with cirrhosis and refractory ascites, with an indication to start NSBB in primary
prophylaxis for variceal bleeding, were enrolled. During two consecutive LVP, while being, respectively, oﬀ and on NSBB,
cardiac output (CO), systemic vascular resistances (SVR), peripheral vascular resistances (PVR), and plasma renin activity
(PRA) were noninvasively assessed. Results. Seventeen patients were enrolled, and 10 completed the study. Before NSBB
introduction, SVR (1896 to 1348 dyn·s·cm−5; p = 0 028) and PVR (47 to 30mmHg·min·dl·ml−1; p = 0 04) signiﬁcantly decreased
after LVP, while CO showed an increasing trend (3.9 to 4.5 l/m; p = 0 06). After NSBB introduction, LVP was not associated
with a signiﬁcant increase in CO (3.4 to 3.8 l/m; p = 0 13) nor with a signiﬁcant decrease in SVR (2002 versus 1798 dyn·s·cm−5;
p = 0 1). Incidence of PICD was not increased after NSBB introduction. Conclusion. The negative inotropic eﬀect of NSBB
was counterbalanced by a smaller decrease of vascular resistances after LVP, probably due to splanchnic β2-blockade. This
pilot study showed that NSBB introduction may be void of detrimental hemodynamic eﬀects after LVP in cirrhotics with
refractory ascites.
1. Introduction
Ascites is the most frequent complication in the natural
history of cirrhosis, and its development is signiﬁcantly
associated with impaired survival [1, 2]. Refractory ascites
(RA) occurs in 5–10% of patients with cirrhosis and ascites,
and it is associated with a signiﬁcant worsening of central
hemodynamics and a further reduction in survival [3].
Development of RA determines hyperdynamic circulation,
peripheral vasodilation, and an impairment of cardiac and
renal function [4].
In this clinical setting, several studies demonstrated
that central hemodynamics could be further worsened by
large volume paracentesis (LVP) in a wide proportion of
patients (15% to 85%), leading to paracentesis-induced cir-
culatory dysfunction (PICD), which has been associated
with decreased survival and shortening of paracentesis-free
interval time [5].
Nonselective beta blockers (NSBB) have been associated
with a reduced survival in patients with RA [6], probably
due to an increased incidence of PICD, suggesting a potential
unfavorable mechanism linked with the worsening of central
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hemodynamics [7]. However, these data were in contrast
with those reported by several studies, in which NSBB were
associated with lower rate of liver decompensation [8],
higher transplant-free survival [9], and a reduced risk of
developing spontaneous bacterial peritonitis [10].
Thus, this prospective study aimed at assessing the role
played by NSBB on central and peripheral hemodynamics
in cirrhotics undergoing LVP for refractory ascites.
2. Materials and Methods
The study was conducted at the Padua University Hospital
Liver Transplant (LT) Center, from December 2013 to
December 2015.
All consecutive patients with cirrhosis listed for LT and
diuretic-intractable or diuretic-resistant refractory ascites—
according to the current guidelines [11]—undergoing repeti-
tive LVP were evaluated. Exclusion criteria were noncirrho-
tic portal hypertension, ongoing chronic antihypertensive
therapy, and nonadherence. Preliminary assessments of
chronic obstructive pulmonary disease, asthma, severe bra-
dycardia, and atrioventricular blocks were performed to rule
out contraindication to NSBB use.
Each patient had to perform an oesophagogastro-
duodenoscopy within 6 months before enrollment. Those
patients having a new indication to start NSBB for primary
prophylaxis of variceal bleeding (e.g., patients with small
varices with red wale marks or Child-Pugh C class; patients
with medium-large varices) were enrolled. Propranolol was
introduced at a starting dose of 40mg twice daily and then
adjusted according to hemodynamic parameters [12]. Repet-
itive LVP were consecutively performed by the same hepatol-
ogist and according to the current guidelines [11].
Central and peripheral hemodynamics were analyzed
before and after two LVP, while being on and oﬀ NSBB ther-
apy. Since hemodynamic measurement was not considered
reliable in patients with bacterial infection or acute kidney
injury, these patients were temporarily excluded from the
study and eventually readmitted only after complete resolu-
tion of acute episodes.
Hemodynamic parameters, such as mean arterial pres-
sure (MAP), cardiac output (CO), cardiac index (CI), heart
rate (HR), were recorded through noninvasive techniques.
MAP was measured (in mmHg) by a Finometer recorder
(Finapres Medical Systems, Amsterdam, The Netherlands),
a standalone solution for accurate automatic blood pressure
system, monitoring and providing automatic heart rate
recording. Cardiac function was measured through the
amount of blood ejected from the left ventricle at each systole
per minute (CO, l/min), by a cardiograph featuring enhanced
bioimpedance signal morphology analysis, obtained through
six leads positioned on the patient’s thorax (PhysioFlow TM-
Patients with refractory 
ascites listed for LT between
 2013 and 2015 
(n = 35)
Enrolled in the study
n = 17 (48.5%)
Completed the study
n = 10 (28.5%)
Drop-out n = 7 (20%)
Excluded n = 18 (51.5%)
(i) Ongoing antihypertensive therapies/cotraindication to NSBB
introduction n = 8 (22.8%)
(ii) Hepatocellular carcinoma n = 3 (8.5%)
(i) NSBB intolerance n = 3 (8.5%)
(ii)
(iii)
Nonadherence/NSBB discontinuation n = 2 (5.7%)
Liver transplantation n = 2 (5.7%)
(iii) Criteria for refractory ascites not fulﬁlled n = 3 (8.5%)
(iv) Nonadherence n = 2 (5.7%)
(v) Noncirrhotic portal hypertension n = 2 (5.7)
Figure 1: Patients’ selection criteria and study design. NSBB: nonselective β-blockers. LT: liver transplantation.
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Lab-1, Manatec Biomedical, Ebersviller, France) [13]. Arte-
rial blood ﬂow indexed for the volume of tissue was measured
at a forearm with a strain gauge plethysmograph (Angioﬂow,
Microlab Electronics, Padua, Italy). This method entails peri-
odic occlusion of venous outﬂow by a cuﬀ automatically
inﬂated at overvenous and underdiastolic pressure, while
the arm’s volume is measured by indium-gallium-in silicone
strain gauges. In such conditions, the segmental blood inﬂow
is proportional to arterial ﬂow, allowing real-time detection
of peripheral ﬂow [14–16]. Peripheral vascular resistances
(PVR) were calculated (in mmHg×min×ml−1) from the
mean blood pressure/forearm ﬂow ratio, while systemic vas-
cular resistances (in dyn× s× cm−5) were calculated from
mean blood pressure/cardiac output ratio [14].
Plasma renin activity (PRA) was measured before LVP
and one hour after the end of LVP from frozen plasma, using
radioimmunoassay technique, similarly to previous studies
[17]. Diagnosis of PICD was made after reaching an increase
greater than 50% than pre-LVP values of PRA at 1 hour after
the end of the procedure. This method was demonstrated to
be as reliable as a measurement of PRA after 7 days of LVP
for PICD detection [7].
All patients were followed up for 12 months, recording
the outcome and eventual decompensation episodes.
All patients gave written informed consent at the time of
enrollment. The study protocol was approved by the local
ethical committee (n.2797P/2013). All diagnostic and thera-
peutic procedures belonging to the protocol were in accor-
dance with the ethical guidelines of the Helsinki Declaration.
3. Statistical Analysis
Noncontinuous variables were assessed as frequencies and
tested using Fisher’s exact test, respectively. Continuous var-
iables were assessed and tested as median (range) and com-
pared using Mann–Whitney U test and Wilcoxon signed
rank test to perform pairwise comparisons, respectively. A
p value < 0.05 was considered statistically signiﬁcant, whereas
a trend towards signiﬁcance was considered when p < 0 08.
Analyses were performed with the SPSS statistical package
(SPSS Inc. version 18.0, 2009, Chicago, IL, USA).
4. Results
4.1. Baseline Characteristics. During the study period,
thirty-ﬁve patients with RA were prospectively evaluated,
of whom 18 (51.4%) were not included for the following
reasons: ongoing chronic antihypertensive therapies or
contraindication to NSBB introduction (n = 8), hepatocel-
lular carcinoma (n = 3), criteria for refractory ascites not
fulﬁlled (n = 3), noncirrhotic portal hypertension (n = 2),
and nonadherence (n = 2). A total of 17 patients (48.5%) were
enrolled, and 10 completed the study. Causes of dropout
were as follows: NSBB intolerance (n = 3), nonadherence/
inappropriate discontinuation (n = 2), and liver transplan-
tation (n = 2) (Figure 1).
All patients enrolled were listed for LT and had diuretic-
intractable refractory ascites, which was treated with subop-
timal diuretic therapy, due to the following: hyperkalemia
(n = 4), impaired renal function (n = 4), and refractory
encephalopathy (n = 2).
The median dose of NSBB was 60mg/day (range 40–
120). All patients fulﬁlled criteria for NSBB dose titration;
NSBB dose was only temporarily reduced in one patient
due to headache and hypotension, without complete with-
drawal, and then titrated to achieve hemodynamic response.
The median drainage volume was 7 liters per procedure
(range 5–12). No signiﬁcant intraindividual diﬀerence in
the drained volume of ascites was found than previous proce-
dure (7 [5–12] versus 7 [5–12], p = 1). During the study,
spontaneous bacterial peritonitis was diagnosed in one
patient; thus, hemodynamic parameters were not considered
reliable and he was temporarily excluded from the study,
until resolution of infection. The characteristics of patients
enrolled in the study are summarized in Table 1.
4.2. Central and Peripheral Hemodynamics. Before NSBB
introduction, SVR showed a signiﬁcant reduction after LVP
(1896 [1276–2293] versus 1348 [925–1804] dyn× s× cm−5;
p = 0 028; Figure 2(a)). Similarly, MAP signiﬁcantly
decreased (82 [71–103] versus 72 [68–86] mmHg, p = 0 03),
whereas CO showed an increasing trend (3.9 [2.8–4.8] versus
4.5 [3.1–4.9] l/m; p = 0 06; Figure 3(a)). Furthermore,
there was a reduction of PVR (47 [36–54] versus 30 [22–
33] mmHg×min×dl×ml−1; p = 0 04). PICD was diagnosed
in 2/10 (20%) patients, after an increase in PRA more
than 50% of the pre-LVP values. There was no signiﬁcant
Table 1: Characteristics of enrolled patients. Continuous variables
are expressed as median (range). BMI: body mass index.
Gender (males), n (%) 4 (40)
Age (years) 57.5 (45–68)
Etiology of liver disease, n (%)
Alcoholic 3 (30)
HCV 2 (20)
HBV 1 (10)
Mixed 4 (40)
BMI 22.7 (19–33)
Serum bilirubin (mg/dl) 1.2 (0.6–3.5)
Serum creatinine (mg/dl) 1.2 (0.6–1.4)
Serum albumin (mg/dl) 34 (33–40)
Previous overt hepatic encephalopathy, n (%) 8 (80%)
MELD score 11 (9–23)
MELD-Na score 16 (14–26)
Child-Pugh score classes, n (%)
A 0
B 4 (40)
C 6 (60)
Propranolol titration dose (mg/day) 60 (40–120)
Diuretic therapy (mg/day)
Potassium canrenoate 200 (100–300)
Furosemide 50 (50–100)
Liters of ascites removed per procedure 7 (5–12)
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diﬀerence between PRA values before and after LVP (9.4
[5.5–14.2] versus 13 [6.4–16.9] ng×ml−1 ×h−1; p = 0 09).
Patients underwent the second LVP after a mean time
of 10 (9–12days) from NSBB introduction. At baseline, no
signiﬁcant diﬀerences were found on hemodynamics than
before previous LVP, except for heart rate, which was sig-
niﬁcantly decreased (76 [range 68–94] versus 63 [range
55–73] bpm; p = 0 05) after NSBB introduction (Table 2).
When performing LVP on NSBB therapy, there was
no signiﬁcant reduction of SVR (2002 [range 1609–2542]
versus 1798 [range 1382–2863] dyn× s× cm−5; p = 0 17;
Figure 2(b)) nor signiﬁcant increase of CO (3.4 [range 2.2–
4.8] versus 3.8 [range 2.1–5.1] l/m; p = 0 13, Figure 3(b))
and of PVR (49 [range 28–53] versus 36 [22–44] mmHg×
min×dl×ml−1; p = 0 2). Nevertheless, MAP signiﬁcantly
decreased after LVP (83 [range 60–96] versus 78 [range 58–
85] mmHg; p = 0 05).
PRA increased 50% more than pre-LVP values in 3
patients, without a signiﬁcant increase in the whole cohort
(6.3 [4.8–9.8] versus 8.6 [4.9–11.6] ng×ml−1 ×h−1; p = 0 07).
No signiﬁcant incidence of PICD was found in compari-
son with the previous LVP.
Patients were followed up for 12 months. All patients
continued NSBB and underwent LVP for RA. During the
follow-up, three patients developed spontaneous bacterial
peritonitis (median time since NSBB introduction: 110
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Figure 2: Systemic vascular resistances before and after large volume paracentesis: (a) before nonselective β-blocker introduction; (b) after
nonselective β-blocker introduction.
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Figure 3: Cardiac output before and after large volume paracentesis: (a) before nonselective β-blocker introduction; (b) after nonselective
β-blocker introduction.
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days [range 10–155]). Hepatorenal syndrome occurred in
two patients after two episodes of bacterial infection
(pneumonia and spontaneous bacterial peritonitis, resp.)
at a median time of 144 days from enrollment. No episode
of variceal bleeding occurred. Cumulative mortality at one
year was 40% (3 patients died of liver failure, 1 patient of
cerebral hemorrhage). Two patients underwent liver trans-
plantation, and one patient dropped out the waiting list
due to alcohol relapse.
5. Discussion
LVP in patients with cirrhosis and RA further enhances
the preexisting hyperdynamic circulation, via a counter-
regulatory overactivation of vasoconstrictor systems. This
can cause renal hypoperfusion and ﬁnally PICD [18, 19].
Data we presented were consistent with those previously
reported on patients undergoing LVP, in whom the reduc-
tion of systemic and peripheral vascular resistances has been
clearly demonstrated [20].
In the setting of RA, it has been postulated that NSBB
could produce further derangements on hemodynamics
and decrease cardiac chronotropic competence [21]. In
our study, NSBB introduction did not impair central
hemodynamics after LVP. The lower increase on CO (3.4
to 3.8 l/m) was associated with a reduced postparacentesis
splanchnic vasodilation. The β2-blockade might determine
a splanchnic vasoconstriction with a smaller post-LVP
decrease of SVR; thus, a smaller increase of CO should be
required to counterbalance hemodynamic changes induced
by LVP.
Regarding hemodynamics, our data were diﬀerent from
those highlighted in the study by Sersté et al. [7], (in which
10/11 patients developed PICD), but in line with other stud-
ies [22–24]. Furthermore, SVR and CO were noninvasively
assessed by bioimpedance analysis, whose reproducibility
and accuracy have been already demonstrated [13, 14, 25,
26]. A study in 45 patients with cirrhosis (half of them with
ascites) demonstrated that total-body bioimpedance analysis
provided reliable and reproducible data regarding compart-
mental volume distribution [27]. Even though this method
has not been validated yet for the assessment of CO in
patients with RA, data provided in our study were similar
to what already demonstrated with invasive techniques
[20]. Moreover, data were collected in the same patient to
avoid interindividual variability and were obtained just from
a thoracic bioimpedance analysis, not being inﬂuenced by
ascites and/or lower limb edema, as in other total-body tech-
niques. Lastly, a noninvasive measurement of central and
peripheral hemodynamics was required due to the design of
the study, by which 4 invasive hemodynamic measurements
would be performed in the same patient.
We can hypothesize that NSBB could produce a new,
although not enough stable, equilibrium, through which sys-
temic organ perfusion is not going impaired unless when
undergoing elevated stressing events. Recently, several stud-
ies provided data on the role of NSBB in decompensated cir-
rhosis [22, 28]; Krag et al. [29] resumed these ﬁndings
hypothesizing a window therapy, which was also discussed
and modiﬁed afterwards [30]. This hypothesis, which seems
to reduce the use of NSBB in cirrhosis, “cutting” the sickest
decompensated patients, remains still matter of discussion
amongst hepatologists [31]. During the follow-up, two
patients developed two episodes of HRS after bacterial infec-
tion. Although a clinical interpretation could not be drawn
due to the small cohort, this observation is in concordance
with the data by Mandorfer et al. [9], who showed a 20%
cumulative incidence of HRS after SBP development in cir-
rhotics treated with NSBB.
The main limitations of this study were the small sample
size, mainly due to strict clinical criteria. The fact that only
58% of patients completed the study because nonadherence
or NSBB intolerance is commonly seen in clinical practice
in patients with decompensated cirrhosis [32]. However, all
patients who completed the study showed a reduction of
heart rate greater than 25% after NSBB introduction.
In conclusion, the negative inotropic eﬀect of NSBB
seems to be counterbalanced by a smaller decrease of vascular
resistances after LVP, probably due to splanchnic β2-block-
ade. This pilot study showed that NSBB introduction may
be void of detrimental hemodynamic eﬀects after LVP in
cirrhotics with refractory ascites.
Table 2: Intraindividual changes of hemodynamic parameters before and after LVP, while being on and oﬀ NSBB. Values are expressed as
median (range). HR: heart rate; MAP: mean arterial pressure; CO: cardiac output; CI: cardiac index; SVR: systemic vascular resistance; PVR:
peripheral vascular resistance; PRA: plasma renin activity. aPre-LVP versus pre-LVP with and without NSBB. bPost-LVP versus post-LVP
with and without NSBB.
Absence of NSBB Presence of NSBB p valuea p valueb
Pre-LVP Post-LVP p value Pre-LVP Post-LVP p value —
HR (bpm) 76 [68–94] 83 [76–89] 0.13 63 [55–73] 74 [60–85] 0.02 0.05 0.08
MAP (mmHg) 82 [71–103] 72 [68–86] 0.03 83 [60–96] 78 [58–85] 0.05 0.3 0.3
CO (l/min) 3.9 [2.8–4.8] 4.5 [3.7–4.9] 0.06 3.4 [3–3.9] 3.8 [3.5–4.1] 0.13 0.2 0.09
CI (l/min/m2) 2.4 [2.1–2.9] 2.8 [2.1–3.1] 0.07 2.1 [2–2.5] 2.3 [2.1–2.9] 0.34 0.5 0.09
SVR (dyn·s·cm−5) 1896 [1276–2293] 1348 [925–1804] 0.028 2002 [1609–2542] 1798 [1382–2863] 0.17 0.5 0.07
PVR
(mmHg·min·dl·ml−1) 47 [36–54] 30 [22–30] 0.04 49 [27–53] 36 [21–44] 0.2 0.8 0.09
PRA (ng·ml−1·h−1) 9.4 [5.3–14.2] 13 [6.4–16.9] 0.09 6.3 [4.8–9.6] 8.6 [4.9–11.6] 0.07 0.07 0.07
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Abbreviations
CO: Cardiac output
CI: Cardiac index
HR: Heart rate
LVP: Large volume paracentesis
MAP: Mean arterial pressure
NSBB: Nonselective beta blockers
PRA: Plasma renin activity
PICD: Paracentesis-induced circulatory dysfunction
PVR: Peripheral vascular resistances
RA: Refractory ascites
SBP: Spontaneous bacterial peritonitis
SVR: Systemic vascular resistances.
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